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Abstract Meconium aspiration syndrome is a serious
neonatal disease with complex pathophysiology. With
respect to the contribution of meconium-induced lung
edema, inflammation and vasoconstriction on the course
of the disease, glucocorticoids are increasingly used in the
treatment of MAS despite the fact that principal questions
on the choice of GCs derivative, mode of delivery and
dosing have not been answered yet. To bring a complex
insight into the topic, this article reviews the pathomechan-
isms of MAS, mechanisms of action of GCs, as well as the
advantages and disadvantages of GCs administration in
experimental models and newborns with MAS.
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Introduction
Meconium aspiration syndrome
Meconium aspiration syndrome (MAS) is a major cause of
respiratory morbidity and mortality in the term and post-
term newborns. The incidence of MAS in the well-
developed countries stands at about one to two per 1,000
live births; however, in the developing countries, this
number may be considerably higher [19]. The clinical
picture varies from mild tachypnoea to life-threatening
respiratory failure associated with pulmonary hypertension
[16]. In addition to acute effects, MAS may also have
serious long-term consequences on the respiratory system,
whereas abnormal bronchial reactivity, wheezing and other
respiratory pathology were found in a considerable portion
of infants who overcome MAS in the neonatal period [80].
Despite an improved understanding of the pathomechan-
isms of MAS and widening the available therapeutic
approach, MAS is often difficult to treat. Therefore, a number
of various adjunctive or alternative approaches have been
tested in MAS. Since some of them have been rather well
established (e.g. different modes of ventilatory support,
surfactant treatment and inhaled nitric oxide), the therapeutic
potential of others (particularly of anti-inflammatory drugs
and vasodilators) is still under research [48].
Pathogenesis of MAS as a rationale for the treatment
by glucocorticoids
The pathogenesis of MAS is complex, with multiple
interactions between the individual pathomechanisms [48].
In an acute phase of the disease, aspirated meconium
obstructs the airways. Complete airway obstruction may
result in alveolar atelectasis behind the plug. Partial airway
obstruction may cause a ball valve effect, and air trapping
and air leak into the interstitium may occur [16].
With the initiation of ventilation, aspirated meconium
reachesthealveoli,whereitinactivatesthesurfactant[56]a n d
triggers inflammation [86]. Meconium changes the viscosity
and ultrastructure of the surfactant [2], decreases the levels
of surfactant proteins [15] and accelerates the conversion
from large, surface active aggregates into small, less active
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DOI 10.1007/s00431-011-1453-2forms [35]. Both fractions of meconium, water-soluble
(containing bilirubin, bile acids, enzymes, etc.) and lipid-
soluble (containing free fatty acids, cholesterol, triglycerides,
etc.) ones, impair lung functions [56]; however, the lipid-
soluble fraction is much more deleterious [76]. The
dysfunction of surfactant is further potentiated by plasma
proteins leaking through an injured alveolocapillary mem-
brane, as well as by the action of proteolytic enzymes and
reactive oxygen and nitrogen species (RONS) released from
activated cells during the inflammation.
Meconium itself acts as a potent chemoattractant for
neutrophils [87], increasing their number in the lungs within
several hours after the aspiration, which is linked with their
decrease in the blood [55, 66]. In addition, meconium is a
source of pro-inflammatory mediators, such as interleukins
(IL) -1, -6 and -8, tumour necrosis factor α (TNFα), etc.
[20]; thus, it may induce inflammation directly or indirectly
through the stimulation of oxidative burst in neutrophils [69]
and alveolar macrophages [17]. The activated macrophages
and released cytokines may stimulate the adhesion of
neutrophils on the endothelium and the formation of micro-
emboli in the capillary bed, participating in the onset of
pulmonary hypertension. This process is facilitated by
complement, the activation of which has been proved also in
MAS [11]. The activated cells (leukocytes, platelets, epithelial
and endothelial cells, etc.) produce a wide spectrum of
substances like TNFα, IL, leukotrienes (LT), prostaglandins
(PG), platelet-activating factor (PAF), proteolytic enzymes and
RONS, injuring the lung parenchyma and surfactant [27, 92].
Inflammatory cytokines induce angiotensin II (ANG II)
expression which, after binding to AT1 receptors, cause
apoptotic death of the lung cells as well [82]. Subsequently,
a leak of proteinaceous fluid and cells into the alveolar spaces
through the alveolocapillary membrane further deteriorates the
lung function. In addition, meconium contains high concen-
trations of phospholipase A2 (PLA2), which may directly or
via the arachidonic acid metabolism increase the production of
lipid mediators and participate in the apoptosis of epithelial
cells [29] and surfactant dysfunction [65]. Meconium also
enhances the expression of inducible cyclooxygenase-2
(COX-2) and inducible nitric oxide synthase (iNOS) in the
macrophages and epithelial and endothelial cells [42, 44].
Furthermore, the release of bronchoactive substances like LT
and PAF is probably responsible for increased airway
reactivity to bronchoconstrictor agents [38, 55].
Meconium aspiration is often associated with pulmonary
vasoconstriction from hypoxia and/or from the vasocon-
striction effect of meconium and substances released during
the inflammation. The presence of meconium in the
amniotic fluid may cause ischemic changes of the lungs,
umbilical cord and placenta [7]. Postnatal meconium
instillation elevates the pulmonary artery pressure and
vascular resistance in a concentration-dependent manner
[28], which is linked with higher levels of thromboxane A2
(TXA2), LT, PG and endothelin-1 (ET-1) [41, 68, 86].
Glucocorticoids
Mechanisms of action
Cortisol, a major endogenous glucocorticoid (GC), is secreted
by the cortex of adrenal glands. Only a small proportion of
GCs (<10%) is free and metabolically active since majority of
GCs is bound to proteins during their transport in the blood.
The daily production of cortisol in adults may be about 13–
20 mg and may increase up to 300 mg/day [75]. In children
and adolescents, the daily production of cortisol is about
6.8 mg/m
2/day [45]. The plasma concentration of cortisol in
adults varies in the range of 50–500 nmol/l, in the term
newborns about 140 nmol/l and in premature newborns about
180 nmol/l [75]. The action of GCs contributes to the
compensatory mechanisms which help the body to get a
stress situation under control. GCs supply energy for these
processes by protein catabolism, gluconeogenesis and gluco-
genesis, finally resulting in hyperglycaemia, hyperlipidemia
and other changes in the blood, bones, muscles and
cardiovascular, gastrointestinal, endocrinal and central ner-
vous systems [24, 34].
Free GC molecules penetrate through the cell membrane
into the cytoplasm, where they interact with a specific
glucocorticoid receptor (GR). Heat-shock protein HSP90,
which is normally attached to a free GR and prevents its
transport to the nucleus, is released in this process. After
binding GCs to a GR receptor, the activated complex moves
into the nucleus and binds to a specific nuclear sequence of
DNA (glucocorticoid-responsive element, GRE). As a result,
it may activate or inhibit the transcription of mRNA and
thereby modulate the production of various proteins (Figs. 1
and 2). The newly synthesized substances then mediate
physiological or pharmacological responses, including met-
abolic and anti-inflammatory effects.
In case of their anti-inflammatory action, the activated
GR complex interacts with negative-responsive element
(GRE
−). The subsequent inhibition of transcription factors
including nuclear factor (NF)-κB and protein activator
(AP)-1 inhibits the expression of pro-inflammatory cyto-
kines (IL-1, IL-6, IL-8, TNFα, etc.), enzymes (PLA2,
COX-2, iNOS, etc.) and other biologically active substan-
ces such as PAF, ET-1, ICAM-1, etc. [24, 34, 57] (Fig. 2).
The anti-inflammatory effect of GCs is supplied also
through enhancing the activity of lipocortines. The in-
creased transcription of lipocortine-1 in leukocytes is
related to the interaction of GC–GR complex to the
positive-responsive element of DNA (GRE
+). Lipocortines
inhibit the activity of PLA2 and thereby decrease the
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ygenase and cyclooxygenase pathway as well as of PAF
[57]. It is assumed that the activation of the cell by a
noxious stimulus causes the inactivation of lipocortines and
development of inflammation. On the contrary, the in-
creased production of lipocortines induced by GCs has
opposite, anti-inflammatory effects [57].
GCs reduce the penetration of neutrophils into the lungs,
decreasing their adherence to the endothelium and thereby
increasing secondarily a count of circulating neutrophils [30,
50, 51, 55, 66]. Moreover, GCs decrease the counts of
circulating mononuclears, eosinophils and basophils as well
as the synthesis of cytokines by macrophages, eosinophils
and T lymphocytes. GCs stabilize lysosomes, inhibit the
release of lysosomal enzymes, chemotaxia and other
functions of neutrophils as well [34]. Furthermore, GCs
stimulate the production of secretion leukocyte protease
inhibitor, an important antiprotease, which may suppress an
inflammation in the airways. GCs facilitate the transcription
of β2-receptor gene and reduce the mast cells count and
production of mucus in the airways, too. By stabilizing the
cell membranes and decreasing the production of pro-
inflammatory and vasoactive substances, GCs reduce micro-
vascular permeability. In addition, by direct modulation of
the pulmonary vasomotoric tone, GCs diminish pulmonary
vasoconstriction and inhibit fibrogenesis [24, 34].
Fig. 1 Genomicandnongenomic
action of glucocorticoids. GC,
glucocorticoid; cGR, cytoplasmic
GC receptor; mGR, membrane-
bound GC receptor; HSP90,h e a t
shock protein 90; Src,p r o t e i n .
For explanation, please see the
text. (Adapted by Buttgereit et al.
[10]a n dS t a h ne ta l .[ 70])
Fig. 2 Trans-activation or trans-
repression of gene caused by
GC–GR binding in cell nucleus.
GC, glucocorticoid; cGR, cyto-
plasmic GC receptor; GRE
+,
positive glucocorticoid respon-
sive element; GRE
−, negative
glucocorticoid responsive ele-
ment; IL, interleukin; AP-1,
protein activator-1; NFκB, nu-
clear factor κB; IRF3, interferon
regulatory factor 3. For expla-
nation, please see the text
Eur J Pediatr (2011) 170:1495–1505 1497Majority of the above-mentioned action of GCs is
mediated by interactions with intracellular cytoplasmic
receptors, leading to the production of protein with specific
regulatory functions. In these genomically mediated pro-
cesses, transcription and translation with subsequent pro-
teosynthesis requires at least several hours until some
changes may be observed on the systemic level. However,
GCs act also through nongenomically mediated mecha-
nisms, which are responsible for rapid GCs action until the
effects mediated by genomic mechanisms occur [71]. In
literature, three possible nongenomic mechanisms are
discussed (Fig. 1): specific interaction with cytosolic GC
receptors (cGCR) and successive release of HSP90 and
special proteins Src and MAPK, non-specific interactions
with cellular membranes and specific interactions with
membrane-bound glucocorticoid receptors. GCs may exert
rapid effects on various tissues and cells, modulating
hormone secretion, neuronal excitability, carbohydrate
metabolism, cell morphology, cell behaviour and other
processes within seconds or minutes [23, 71]. The GC
action may be related to affecting ion cycling [81], cellular
energy metabolism [8] or neuronal activity [12], as well as
to rapid effects on second messenger systems [8]. In the
respiratory system, GCs presumably via nongenomic action
modulated Na
+/H
+ exchange activity in bronchial epithelial
cells [81] and inhibited airway smooth muscle contraction
within 10 min after GCs inhalation [73, 91]. Similarly, in a
rabbit model of MAS, GCs already significantly improved
several respiratory parameters within 30 min after the
administration [50, 51].
In addition, interactions between genomic and non-
genomic mechanisms have been claimed, thereby control-
ling genomic mechanisms through nongenomic ones [85].
Nongenomic effects occur faster and may be clinically
relevant over a limited period, “bridging the gap” until the
long-term genomic effects take place [9].
Irrespective of the mechanisms of their action, GCs may
effectively suppress polymorphonuclear inflammation, lung
edema formation and pulmonary vasoconstriction. Howev-
er, the effect of the treatment depends on the specific
properties, dose and mode of delivery of the individual GCs
as well as on the current status of the newborn or
experimental animal with MAS.
Glucocorticoids in the treatment of MAS
Despite GCs having been used in various animal models of
MAS as well as in several clinical studies, some questions
still remain unanswered. Particularly:
1. According to the pharmacological properties, which of
the available synthetic GC preparations is the best
choice—i.e. most effective with low side effects?
2. What way of GCs administration is better—intravenous
or intratracheal?
3. What dosing and timing should be used? When to
administer GCs and in what dose per individual GCs
preparation? Is it better to use single or repetitive doses
of the GC preparative?
4. Is it possible to combine GCs with other drugs
emphasizing their favourable effects?
Pharmacological properties of GCs preparations
Individual GCs may exert different pharmacological prop-
erties including different mineralocorticoid activity. Al-
though accepted in practice, the clinical potencies of GC
preparations have been difficult to assess using classical
approaches. For example, the potency of GCs to suppress
cortisol production does not sufficiently reflect the ability to
suppress inflammation [21]. In addition, it is suggested that
different GCs may have different potency per target tissue.
The basic characteristics of commonly prescribed GCs
preparations are listed in Table 1.
In addition, regarding their nongenomic action, the
relative drug potency of individual GCs may differ from
the hierarchy for the classic genomic effects. For example,
assessing some rapid nongenomic effects, dexamethasone
was shown to be the most potent among the tested GCs,
thanks probably to the lowest lipophilicity facilitating its
interaction directly with the cell membrane [9, 46, 64, 79].
Side effects of GCs
The administration of GCs may be accompanied by mostly
unwanted side effects due to their influencing the physiolog-
ical processes in the body. The occurrence and intensity of
adverse effects depend on the type of GCs preparation,
dosing, timing and way of administration. While adverse
effects are rare in the administration of low (“physiological”
or “substitutional”) doses of GCs in substitution therapy, the
long-term administration of high (“pharmacological” or
“supraphysiological”) doses of GCs may be associated with
the side effects of various characters. GC drugs suppress the
function of the hypothalamic–pituitary–adrenal axis, decreas-
ing the secretion of corticotropin, which in turn reduces the
secretion of cortisol by adrenal glands. Prolonged adrenal
suppression may cause reduced responses to stress [3]. In
addition, long-term GCs administration may lead to hyper-
glycaemia, hypokalemia, dyslipidemia, reduced fibrinolysis,
hypertension, posterior subcapsular cataract, exacerbation of
glaucoma, increased intracranial pressure, peptic ulcers,
upper gastrointestinal bleeding, immunosuppression, neuro-
psychiatric disturbances, osteoporosis, myopathy, irregulari-
ties of the menstruation cycle, etc. [63].
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effects of systemic GCs, the local administration of GCs is
generally preferred. However, depending on the system of
delivery and dose used, <20% of the nebulized GCs is
deposited into the lungs and the rest may be absorbed into
the circulation from the gastrointestinal system and subse-
quently cause systemic effects [61]. In addition, inhalation
of GCs may worsen the course of bacterial infections after
initial improvement and may increase the risk of oropha-
ryngeal candidiasis, dysphonia, cough, throat irritation and
other local side effects [3].
Use of GCs in perinatal respiratory diseases
In respirology, GCs (mainly inhalational GCs such as
budesonide) are used in asthma and exacerbations of
chronic obstructive pulmonary disease [6, 43, 61]. In
perinatal period, GCs may be administered antenatally or
postnatally. Antenatal GCs (particularly betamethasone and
dexamethasone) are used to induce early lung maturation
and stimulate the synthesis of pulmonary surfactant in
premature infants [5, 60]. Postnatally, GCs (especially
dexamethasone) take part in the treatment of chronic lung
disease or bronchopulmonary dysplasia after neonatal
respiratory distress syndrome [1, 40, 83]. However, long-
term GCs administration may exert adverse effects on
neuromotor function and the somatic growth of the treated
infants [89]. In adult/acute respiratory distress syndrome,
GCs (mostly methylprednisolone) may be of benefit in
fibroproliferative or late phase of the disease, but use in the
early stages of the disease is controversial [24, 34].
Use of GCs in MAS
In animal models and in newborns with MAS, hydrocor-
tisone, prednisolone, methylprednisolone, dexamethasone
and budesonide have been used, with the subjects having
various responses to treatment.
Hydrocortisone is a synthetic equivalent of cortisol and
used as an immunosuppressive drug in severe allergic
reactions such as anaphylaxis and angioedema. Comparing
the strength for the anti-inflammatory effect, prednisolone
is about four times and dexamethasone is about 30 times
stronger than hydrocortisone. Thanks to both glucocorticoid
and mineralocorticoid effects, hydrocortisone may be used
in substitution therapy; however, expressing mineralocorti-
coid activity, hydrocortisone may potentiate a dysbalance of
liquids and electrolytes in the body.
In the study by Frantz et al. [25] carried out in 1975, the
subcutaneous administration of hydrocortisone at a dose of
7.5 mg/kg immediately after meconium instillation and then
every 8 h up to 48 h non-significantly improved the
histology of the lungs and decreased the frequency of
breathing in newborn rabbits. However, a higher mortality
of the hydrocortisone-treated animals was observed irre-
spective if they aspired meconium or saline, probably due
to the infection at the tracheotomy site and sepsis [25]. Two
years later, hydrocortisone, at a dose of 20 mg/kg, was
Agent Activity Equivalent oral
dose (mg)
Forms
available
Anti-inflammatory Topical Salt-retaining
Short- to medium-acting GCs
Hydrocortisone (cortisol) 1 1 1 20 p.o., inj., top.
Cortisone 0.8 0 0.8 25 p.o.
Prednisone 4 0 0.3 5 p.o., inj.
Prednisolone 5 4 0.3 5 p.o., inj.
Methylprednisolone 5 5 0 4 p.o., inj.
Meprednisone 5 – 0 4 p.o., inj.
Intermediate-acting GCs
Triamcinolone 5 5 0 4 p.o., inj., top.
Paramethasone 10 – 0 2 p.o., inj.
Fluprednisolone 15 7 0 1.5 p.o.
Long-acting GCs
Betamethasone 25–40 10 0 0.6 p.o., inj., top.
Dexamethasone 30 10 0 0.75 p.o., inj., top.
Mineralocorticoids
Fludrocortisone 10 0 250 2 p.o.
Desoxycorticosterone acetate 0 0 20 – p.o., inj.
Table 1 Basic characteristics of
commonly used natural and
synthetic corticosteroids [36]
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17 neonates with MAS [88]. Blood gases, X-ray, incidence
of pneumothorax or pneumomediastinum, requirements for
mechanical ventilation and mortality were comparable in
the hydrocortisone-treated vs. placebo-administered group.
However, longer period to wean to room air and remaining
clinical signs of respiratory distress were observed in the
treated group than in controls [88]. We may speculate that
no benefit of the treatment may be caused by low dose or
by late treatment, respectively, since the first dose of
hydrocortisone was administered at about 5 h of age [88]
when severe respiratory distress and inflammation have
already been developed. No effect of hydrocortisone on
meconium-induced lung edema in the study by Frantz et al.
[25] may be explained by fluid retention in the lungs or
delayed reabsorption of the fluid due to mineralocorticoid
action of hydrocortisone. In addition, the anti-inflammatory
potential of hydrocortisone is several times weaker than that
of other GCs.
Prednisolone is a GC drug with predominant glucocor-
ticoid and low mineralocorticoid activity. Thanks to its
strong anti-inflammatory and immunosuppressive action, it
is used for the treatment of a wide range of inflammatory
and auto-immune disorders, such as bronchial asthma,
rheumatoid arthritis, ulcerative colitis, etc.
In the study by Kirimi et al. [39], the intravenous
administration of prednisolone at standard (2 mg/kg) and
high (30 mg/kg) doses immediately after meconium
instillation improved gas exchange and increased the
frequency of breathing in meconium-instilled puppies in
comparison with the non-treated group. In addition, high-
dose prednisolone showed a more obvious improvement in
lung histology compared to the standard dose, without
hyperglycaemia or hypertension as side effects. However,
high-dose prednisolone significantly increased the plasma
levels of malonyldialdehyde, product of lipid peroxidation,
compared to standard-dose group and controls at 20 h after
meconium aspiration. It may suggest a paradoxically lower
effectivity of high-dose vs. standard-dose prednisolone in
the reduction of oxidation stress resulting from inflamma-
tion or even the potentiation of oxidation stress by a mega-
dose of prednisolone [39]. Nevertheless, the value of this
information is limited by the small number of animals
included in the treated groups (n=3 each).
Methylprednisolone, a methylated derivative of prednis-
olone, has similar properties and use as prednisolone. Since
it may reach higher concentrations in the lungs than
prednisolone due to a higher distribution volume, slower
elimination and higher accumulation in the alveolar
epithelium, it is used also for the short-term treatment of
bronchial inflammation or acute bronchitis.
Soukka et al. [66] found that, in 10-week-old pigs with
MAS, pretreatment with methylprednisolone (30 mg/kg, i.
v.) 30 min before the instillation of meconium tended to
prevent an early (0–1 h) increase in pulmonary artery
pressure and significantly inhibited the second-phase (1–
6 h) progressive rise in pulmonary artery pressure and
pulmonary vascular resistance, decreased venous admixture
and formation of lung edema and improved oxygenation
[66]. In another study by Soukka et al. [67], premedication
with methylprednisolone decreased the level of endothelin
(ET)-1 and increased the level of atrial natriuretic peptide
(ANP). The modulation of the ratio ET-1/ANP for ANP
diminished pulmonary hypertension and indicated the
protective effect of GCs on the endothelium-mediated
regulation of the pulmonary vascular tone [67]. Thus,
premedication with GCs before the labour might be
beneficial in the case of verified massive meconium
staining of the amniotic fluid and prenatal meconium
aspiration to reduce remodelling of the pulmonary vascular
lining and lung inflammation. However, up to this time, no
clinical study was performed to evaluate the possible
benefits of prenatal GCs delivery in MAS.
Postnatally, methylprednisolone has been recently used
in two trials carried out in India [4, 77, 78]. Methylpred-
nisolone administered for a period of 7 days starting after
24 h of age in 34 newborns with MAS shortened the period
of oxygen delivery and duration of hospital stay and
improved the radiological clearance of the lungs, while no
serious adverse effects including sepsis were observed [4].
In the study by Tripathi and co-workers [77, 78],
methylprednisolone was given in 17 newborns with MAS
at a dose of 0.5 mg/kg/day, i.v., in two divided doses every
12 h for 7 days. Similarly to the study by Basu et al. [4],
methylprednisolone shortened the duration of stay, oxygen
dependence and X-ray of the lungs, decreased the levels of
TNFα in tracheal aspirate and did not increase the
incidence of sepsis.
Dexamethasone is a synthetic GC with potent anti-
inflammatory and immunosuppressive action. It is >30
times stronger than hydrocortisone and about five times
stronger than prednisone. Dexamethasone is also used for
diagnostic procedures (to suppress the natural pituitary–
adrenal axis) in obstetrics to promote the maturation of
foetal lungs as well as in a wide spectrum of endocrine,
oncological and other diseases.
The first successful use of dexamethasone in MAS has
been referred to in the 1990s, when it improved pulmonary
ventilation and facilitated weaning from the ventilator in
several newborns with severe MAS [86]. Later, numerous
experimental and clinical studies evaluated the efficacy and
management of dexamethasone administration in the con-
ditions of MAS. Commonly, dexamethasone at a dose of
0.5 mg/kg body weight has been used.
However, the timing of dexamethasone delivery appears
to be critical for the effectiveness of treatment. In
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sone (1 h before meconium instillation) reduced pulmonary
vascular resistance and lung edema, improved oxygenation
and prevented ultrastructural changes of the lungs [30].
Similarly, the early administration of dexamethasone
(30 min after meconium instillation) significantly reduced
right-to-left pulmonary shunting, improved gas exchange
and decreased ventilatory pressures in meconium-instilled
rabbits compared to non-treated controls [50]. Furthermore,
early dexamethasone decreased the neutrophil count in
BAL fluid and reduced lung edema, meconium-induced
tracheal hyperreactivity to histamine and concentrations of
lipid and protein peroxidation products in the lung
homogenate compared to controls [50, 55]. On the other
side, the late administration of dexamethasone (1 h after
meconium instillation) led to only non-significant improve-
ment of oxygenation and had no effect on lung edema in
piglets with MAS [30]. The results have clearly showed a
better effect of GCs in early administration occurring before
extensive tissue response to the meconium instillation.
Considering time-related inflammatory changes in MAS,
limitations of the treatment efficacy in late administration of
GCs may be reduced by repetitive administration. It is
known that the action of dexamethasone is fast, but of a
short term. The half-life of dexamethasone in adults is 110–
190 min, with the biological half-life of 36–72 h [14, 74].
In newborns, the plasma half-life of dexamethasone is 150–
300 min and the biological half-life is between 36–54 h
[47]. Therefore, in acute situations, repetitive administration
every 2–4 h is recommended (data given by the producer,
Dexamed, Medochemie, Cyprus).
In meconium-instilled piglets, two-phase dexamethasone
administration at 2 and 8 h after meconium instillation
significantly improved gas exchange and lung compliance
compared to controls [37]. In a rabbit model of MAS, the
repetitive administration of dexamethasone 0.5 and 2.5 h
after meconium instillation suppressed inflammation and
enhanced gas exchange more effectively than a single dose
administered 0.5 h after meconium [50, 52]. Similarly, in
newborns with MAS, dexamethasone administered in
gradually decreasing doses within maximally 9 days (at a
dose of 0.5, 0.25 and 0.125 mg/kg/day, each administered
for 3 days) decreased the oxygenation index and facilitated
weaning from the ventilator [18].
Nevertheless, high doses of systemic GCs or their
repetitive administration may exert various undesirable
effects. Although the acute cardiovascular changes may be
critical for neonates with meconium-induced lung injury, the
side effects of repetitive GCs administration in MAS have not
been investigated yet in a clinical study. In a rabbit model of
MAS, the slow intravenous administration of one dose, but
especially of two doses of dexamethasone, was associated
with acute changes of blood pressure, heart rate and heart rate
variability within 5 h of treatment [52, 54]. A detailed
analysis of cardiovascular changes showed increased blood
pressure, decreased heart rate, increased heart rate variability
and a higher occurrence of cardiac arrhythmias particularly
during and immediately after dexamethasone administration,
while decreased heart rate and increased heart rate variability
were observed until the end of the observation period (i.e.
5 h after the first dose of dexamethasone) [52, 54].
Budesonide is an inhalational GC used in the treatment of
bronchial asthma, non-infectious rhinitis (including hay fever
and other allergies) and nasal polyposis. Budesonide has high
first-pass metabolism and its administration is associated with
a lower incidence of systemic manifestations than with other
GCs (fewer bone density losses and little influence on the
hypothalamic–pituitary–adrenal axis) [3, 31].
In meconium-instilled rabbits, budesonide (Pulmicort,
0.25 mg/kg) was administered intratracheally 30 min after
meconium instillation and then 2 h later using the inpulsion
effect of high-frequency jet ventilation (inspiration time
20%). The treatment effectively alleviated inflammation,
decreased lung edema formation and meconium-induced
tracheal and lung smooth muscle hyperreactivity to hista-
mine, improved gas exchange and decreased the oxidation
injury of the lungs compared to non-treated controls [51].
In addition, intratracheal budesonide administration was
associated with negligible acute cardiovascular effects [49]
compared to dexamethasone [52, 54].
In 32 newborns with MAS, budesonide administered for
a period of 7 days starting after 24 h of age shortened the
period of oxygen delivery and duration of hospital stay and
improved the radiological clearance of the lungs, while no
serious adverse effects were found [4]. In another study [77,
78], budesonide was given in 17 newborns with MAS at a
dose of 50 μg/kg/day, i.v., in two divided doses every 12 h
for 7 days. Comparably to Basu et al. [4], budesonide
shortened the duration of stay, oxygen dependence and X-
ray of the lungs, decreased the levels of TNFα in tracheal
aspirate and did not increase the incidence of sepsis.
Local administration predisposes the inhalational GCs to
be faster and of more potent action at the site of
inflammation. Thanks to high lipophility, inhalational GCs
(budesonide) have rapid direct effects on cells involved in
airway inflammation including macrophages, eosinophils,
T lymphocytes and airway epithelial cells [3]. In in vitro
comparison of potency to reduce a release of IL-8 from
airway epithelial cells, budesonide has shown ten-times-
stronger activity than dexamethasone [59]. It corresponds
well with our findings in the rabbit model of MAS, where
intratracheal budesonide improved gas exchange and
reduced lipid and protein peroxidation in the lung tissue
more effectively compared to dexamethasone. In addition,
budesonide reduced both tracheal and lung smooth muscle
hyperresponsiveness to histamine, while dexamethasone
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tissue [50, 51]. Nevertheless, in the above-mentioned
clinical studies [4, 77, 78], no differences between the
methylprednisolone- and budesonide-treated groups were
found. Similarly, inhaled GCs (beclomethasone) showed no
priority to intravenous GCs (dexamethasone) in ventilator-
dependent preterm newborns [72].
We may speculate that the absence of superior action of
locally administered GCs to systemic GCs may be related to
t h em e t h o do fa d m i n i s t r a t i o nu s e d —nebulization. Consider-
ing high extrapulmonal losses (>80%) of nebulized material
[61], other ways of administration, such as slow administra-
tion directly into the trachea, should be considered. In our
study, budesonide administered via inpulsion effect of HFJV
effectively improved the lung functions with minimum
losses of the drug and negligible side effects [49, 51].
Intratracheal administration of GCs may be further mitigated
by the use of suitable vehicle, e.g. saline or exogenous
surfactant [22]. In experimental conditions, an addition of
GCs to exogenous surfactant did not alter the surface
properties of the surfactant and GCs were well distributed
throughout the lungs with 30–60% of the delivered material
detected in the lung tissue [58]. In preterm infants, intra-
tracheal instillation of a mixture of budesonide (0.25 mg/kg)
and beractant (100 mg/kg) every 8 h decreased the mean
airway pressure, oxygenation index and PCO2 and reduced
deaths and chronic lung disease at 36th week of postconcep-
tional age compared to the group treated solely by Survanta
(100 mg/kg, every 8 h) [90].
Combinations of GCs with other drugs
Regarding the results of experimental and clinical studies,
GCs may show some benefit in the treatment of MAS.
However, due to the complex and multifactorial pathophys-
iology of the disease, other drugs (e.g. exogenous surfactant)
should be included in the therapeutic scheme, too. In
newborns with MAS, intravenous dexamethasone at a single
dose of 0.5 mg/kg was administered within the first 5 h of life
prior toa bronchoalveolar lavageusing beractant (5mg/ml)in
a volumeof15 ml/kg infouraliquots[62]. The authors found
that the surfactant lung lavage in combination with dexa-
methasone pretreatment may improve the status of the
newborns with MAS more effectively than the surfactant
lavage alone [62]. Similarly, in animal models of acute lung
injury, the combination of dexamethasone with exogenous
surfactant showed an additional improvement to the surfac-
tant treatment alone [13, 26].
By utilization of their synergic or additive effects, GCs
may be well combined also with other medicaments, e.g.
with methylxanthine derivatives such as theophylline [32],
with antioxidants such as N-acetylcysteine [33] or with β2-
agonists such as terbutaline [84]. In the experimental model
of MAS, intratracheal budesonide followed by the intrave-
nous administration of aminophylline improved the lung
functions more effectively than aminophylline alone [53].
Concluding remarks
Despite the increasing number of trials with GCs in
experimental models and newborns with MAS, their
administration is still missing in the generally accepted
therapeutic protocol of MAS. However, favourable results
from the studies indicate that GCs may be beneficial,
particularly in severe forms of MAS with apparent lung
edema, pulmonary vasoconstriction and inflammation.
Summarizing all mentioned data, in the future, the
research activities should be focused on an appropriate
dosing, timing and ways of administration of GCs
considering their individual properties and possible acute
and long-term side effects. Since the causal treatment of
MAS should consist of several agents, it is necessary to
also verify the promising combinations of GCs with other
drugs, particularly with exogenous surfactant, anti-
inflammatory drugs and pulmonary vasodilators.
Acknowledgement This work was supported by “Center of Excel-
lence for Perinatology Research” Project No. 26220120016 co-
financed by EU sources and by Ministry of Education VEGA Project
Nos. 1/0061/08, 1/0057/11 and 1/0030/11.
Conflicts of interest The authors have no financial relationship with
the organization that sponsored the research.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Anttila E, Peltoniemi O, Haumont D, Herting E, ter Horst H,
Heinonen K, Kero P, Nykänen P, Oetomo SB, Hallman M (2005)
Early neonatal dexamethasone treatment for prevention of broncho-
pulmonary dysplasia. Randomised trial and meta-analysis evaluating
the duration of dexamethasone therapy. Eur J Pediatr 164:472–481
2. Bae CW, Takahashi A, Chida S, Sasaki M (1998) Morphology
and function of pulmonary surfactant inhibited by meconium.
Pediatr Res 44:187–191
3. Barnes PJ (1995) Inhaled glucocorticoids for asthma. N Engl J
Med 332:868–875
4. Basu S, Kumar A, Bhatia BD, Satya K, Singh TB (2007) Role of
steroids on the clinical course and outcome of meconium
aspiration syndrome—a randomized controlled trial. J Trop
Pediatr 53:331–337
5. Baud O (2004) Antenatal corticosteroid therapy: benefits and
risks. Acta Paediatr Suppl 93:6–10
1502 Eur J Pediatr (2011) 170:1495–15056. Bryan SA, Leckie MJ, Hansel TT, Barnes PJ (2000) Novel
therapy for asthma. Expert Opin Investig Drugs 9:25–42
7. Burgess AM, Hutchins GM (1996) Inflammation of the lungs,
umbilical cord and placenta associated with meconium passage in
utero. Review of 123 autopsied cases. Pathol Res Pract 192:1121–
1128
8. Buttgereit F, Scheffold A (2002) Rapid glucocorticoid effects on
immune cells. Steroids 67:529–534
9. Buttgereit F, Brand MD, Burmester GR (1999) Equivalent doses
and relative drug potencies for non-genomic glucocorticoid
effects: a novel glucocorticoid hierarchy. Biochem Pharmacol
58:363–368
10. Buttgereit F, Straub RH, Wehling M, Burmester GR (2004)
Glucocorticoids in the treatment of rheumatic diseases: an
update on the mechanisms of action. Arthritis Rheum 50:3408–
3417
11. Castellheim A, Lindenskov PH, Pharo A, Aamodt G, Saugstad OD,
Mollnes TE (2005) Meconium aspiration syndrome induces
complement-associated systemic inflammatory response in newborn
piglets. Scand J Immunol 61:217–225
12. Chen YZ, Qiu J (2001) Possible genomic consequence of
nongenomic action of glucocorticoids in neural cells. News
Physiol Sci 16:292–296
13. Chen CM, Fang CL, Chang CH (2001) Surfactant and corticosteroid
effects on lung function in a rat model of acute lung injury. Crit Care
Med 29:2169–2175
14. Chin R Jr, Eagerton DC, Salem M (1994) Corticosteroids. In:
Chernow B (ed) The pharmacologic approach to the critically ill
patient, 3rd edn. Williams & Wilkins, Baltimore, pp 715–740,
1994
15. Cleary GM, Antunes MJ, Cieselka DA, Higgins ST, Spitzer AR,
Chander A (1997) Exudative lung injury is associated with
decreased levels of surfactant proteins in a rat model of meconium
aspiration. Pediatrics 100:998–1003
16. Co E, Vidyasagar D (1990) Meconium aspiration syndrome.
Compr Ther 16:34–39
17. Craig S, Lopez A, Hoskin D, Markham F (2005) Meconium
inhibits phagocytosis and stimulates respiratory burst in alveolar
macrophages. Pediatr Res 57:813–818
18. da Costa DE, Nair AK, Pai MG, Al Khusaiby SM (2001) Steroids
in full term infants with respiratory failure and pulmonary
hypertension due to meconium aspiration syndrome. Eur J Pediatr
160:150–153
19. Dargaville PA, Copnell B, Australian and New Zealand Neonatal
Network (2006) The epidemiology of meconium aspiration
syndrome: incidence, risk factors, therapies, and outcome.
Pediatrics 117:1712–1721
20. de Beaufort AJ, Bakker AC, van Tol MJD, Poorthuis BJ, Schrama
AJ, Berger HM (2003) Meconium is a source of pro-inflammatory
substances and can induce cytokine production in cultured A549
epithelial cells. Pediatr Res 54:491–495
21. Dubois EFL (2005) Clinical potencies of glucocorticoids: what do
we really measure? Curr Respir Med Rev 1:103–108
22. Fajardo C, Levin D, Garcia M, Abrams D, Adamson I (1998)
Surfactant versus saline as a vehicle for corticosteroid delivery to
the lungs of ventilated rabbits. Pediatr Res 43:542–547
23. Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M
(2000) Multiple actions of steroid hormones—a focus on rapid,
nongenomic effects. Pharmacol Rev 52:513–556
24. Fernandes ABS, Zin WA, Rocco PRM (2005) Corticosteroids in
acute respiratory distress syndrome. Braz J Med Biol Res 38:147–
159
25. Frantz ID, Wang NS, Thach BT (1975) Experimental meconium
aspiration: effects of glucocorticoid treatment. J Pediatr 86:438–
441
26. Häfner D, Germann PG (1999) Dexamethasone enhances the
activity of rSP-C surfactant but not of exosurf in a rat model of the
acute lung injury. J Pharmacol Toxicol Methods 42:39–48
27. Hageman JR, Caplan MS (1995) An introduction to the structure
and function of inflammatory mediators for clinicians. Clin
Perinatol 22:251–261
28. Holopainen R, Soukka H, Halkola L, Kääpä P (1998)
Meconium aspiration induces a concentration-dependent pul-
monary hypertensive response in newborn piglets. Pediatr
Pulmonol 25:107–113
29. Holopainen R, Aho H, Laine J, Peuravuori H, Soukka H, Kääpä P
(1999) Human meconium has high phospholipase A2 activity and
induces cellular injury and apoptosis in piglet lungs. Pediatr Res
46:626–632
30. Holopainen R, Laine J, Halkola L, Aho H, Kääpä P (2001)
Dexamethasone treatment attenuates pulmonary injury in piglet
meconium aspiration. Pediatr Res 49:162–168
31. Hvizdos KM, Jarvis B (2000) Budesonide inhalation suspension:
a review of its use in infants, children and adults with
inflammatory respiratory disorders. Drugs 60:1141–1178
32. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM,
Barnes PJ (2002) A molecular mechanism of action of theophyl-
line: induction of histone deacetylase activity to decrease
inflammatory gene expression. Proc Natl Acad Sci USA
99:8921–8926
33. Jansson AH, Eriksson C, Wang X (2005) Effects of budesonide
and N-acetylcysteine on acute lung hyperinflation, inflammation
and injury in rats. Vascul Pharmacol 43:101–111
34. Jantz MA, Sahn AS (1999) Corticosteroids in acute respiratory
failure. Am J Respir Crit Care Med 160:1079–1100
35. Kakinuma R, Shimizu H, Ogawa Y (2002) Effect of meconium on
the rate of in vitro subtype conversion of swine pulmonary
surfactant. Eur J Pediatr 161:31–36
36. Katzung BG (ed) (2007) Basic and clinical pharmacology, 10th
edn. McGraw-Hill Medical, 1179 p. ISBN 978-007-126093-0
37. Khan AM, Shabarek FM, Kutchback JW, Lally KP (1999) Effects
of dexamethasone on meconium aspiration syndrome in newborn
piglets. Pediatr Res 46:179–183
38. Khan AM, Elidemir O, Epstein CE, Lally KP, Xue H, Blackburn
M, Larsen GL, Colasurdo GN (2002) Meconium aspiration
produces airway hyperresponsiveness and eosinophilic inflamma-
tion in a murine model. Am J Physiol Lung Cell Mol Physiol 283:
L785–L790
39. Kirimi E, Tuncer O, Kösem M, Ceylan E, Tas A, Tasal I,
Balahoroğlu R, Caksen H (2003) The effects of prednisolone and
serum malondialdehyde levels in puppies with experimentally
induced meconium aspiration syndrome. J Int Med Res 31:113–
122
40. Kopelman AE, Moise AA, Holbert D, Hegemier SE (1999) A
single very early dexamethasone dose improves respiratory and
cardiovascular adaptation in preterm infants. J Pediatr 135:345–
350
41. Kuo CY, Chen JY (1999) Effects of meconium aspiration on
plasma endothelin-1 level and pulmonary hemodynamics in a
piglet model. Biol Neonate 76:228–234
42. Kytola J, Kääpä P, Uotila P (2003) Meconium aspiration stimulates
cyclooxygenase-2andnitricoxidesynthase-2expressioninratlungs.
Pediatr Res 53:731–736
43. Leckie MJ, Bryan SA, Hansel TT, Barnes PJ (2000) Novel
therapy for COPD. Expert Opin Investig Drugs 9:3–23
44. Li YH, Yan ZQ, Brauner A, Tullus K (2001) Meconium induces
expression of inducible NO synthase and activation of NF-κBi n
rat alveolar macrophages. Pediatr Res 49:820–825
45. Linder BL, Esteban NV, Yergey AL, Winterer JL, Loriaux DL,
Cassorl F (1990) Cortisol production rate in childhood and
adolescence. J Pediatr 117(6):892–896
Eur J Pediatr (2011) 170:1495–1505 150346. Lösel R, Wehling M (2003) Nongenomic actions of steroid
hormones. Nat Rev Mol Cell Biol 4:46–56
47. Miller WL, Achermann JC, Flück CE (2008) The adrenal cortex
and its disorders. In: Sperling MA (ed) Pediatric endocrinology,
3rd edn. Saunders Elsevier, Philadelphia, pp 444–511, 2008
48. Mokra D, Mokry J (2010) Meconium aspiration syndrome. From
pathomechanisms to treatment. Nova, New York, p 130 p. ISBN
978-1-60876-944-5
49. Mokra D, Calkovska A, Tonhajzerova I, Petraskova M, Bulikova J,
Redfors B, Javorka K (2007) Intratracheal budesonide improved the
lung functions in meconium-instilled rabbits without side effects on
cardiovascular functions. Eur Respir J 30(Suppl 51):396 p
50. Mokra D, Mokry J, Drgova A, Bulikova J, Petraskova M,
Calkovska A (2007) Single-dose vs. two-dose dexamethasone
effects on lung inflammation and airway reactivity in
meconium-instilled rabbits. J Physiol Pharmacol 58(Suppl
5):379–387
51. Mokra D, Mokry J, Drgova A, Petraskova M, Bulikova J,
Calkovska A (2007) Intratracheally administered corticosteroids
improved the lung functions in meconium-instilled rabbits. J
Physiol Pharmacol 58(Suppl 5):389–398
52. Mokra D, Calkovska A, Tonhajzerova I, Petraskova M, Bulikova
J, Redfors B (2008) Dexamethasone treatment improved lung
functions in meconium-instilled rabbits, but influenced cardiovas-
cular variables. Bratisl Med J 109:95–101
53. Mokra D, Drgova A, Mokry J, Bulikova J, Pullmann R, Durdik P,
Petraskova M, Calkovska A (2008) Combination of budesonide
and aminophylline diminished acute lung injury in animal model
of meconium aspiration syndrome. J Physiol Pharmacol 59(Suppl
6):461–471
54. Mokra D, Tonhajzerova I, Mokry J, Drgova A, Petraskova M,
Calkovska A, Javorka K (2008) Rapid cardiovascular effects of
dexamethasone in rabbits with meconium-induced acute lung
injury. Can J Physiol Pharmacol 86:804–814
55. Mokry J, Mokra D, Antosova M, Bulikova J, Calkovska A,
Nosalova G (2006) Dexamethasone alleviates meconium-induced
airway hyperresponsiveness and lung inflammation in rabbits.
Pediatr Pulmonol 41:55–60
56. Moses D, Holm BA, Spitale P, Liu M, Enhorning G (1991)
Inhibition of pulmonary surfactant function by meconium. Am J
Obstet Gynecol 164:477–481
57. Newton R (2000) Molecular mechanisms of glucocorticoid action:
what is important? Thorax 55:603–613
58. Nimmo AJ, Carstairs JR, Patole SK, Whitehall J, Davidson K, Vink
R (2002) Intratracheal administration of glucocorticoids using
surfactant as a vehicle. Clin Exp Pharmacol Physiol 29:661–665
59. Pan NY, Hui WS, Tipoe GL, Taylor GW, Leung RY, Lam WK,
Tsang KW, Mak JC (2006) Inhibition of pyocyanin-potentiated
IL-8 release by steroids in bronchial epithelial cells. Respir Med
100:1614–1622
60. Purdy IB, Wiley DJ (2004) Perinatal corticosteroids: a review of
research. Part I: antenatal administration. Neonatal Netw 23:15–30
61. Rizzo MC, Solé D (2006) Inhaled corticosteroids in the treatment
of respiratory allergy: safety vs. efficacy. J Pediatr (Rio J) 82:
S198–S205
62. Salvia-Roiges MD, Carbonell-Estrany X, Figueras-Aloy J, Rodríguez-
Miguélez JM (2004) Efficacy of three treatment schedules in severe
meconium aspiration syndrome. Acta Paediatr 93:60–65
63. Schäcke H, Döcke W-D, Asadullah K (2002) Mechanisms involved
in the side effects of glucocorticoids. Pharmacol Ther 96:23–43
64. Schmid D, Burmester GR, Tripmacher R, Kuhnke A, Buttgereit F
(2000) Bioenergetics of human peripheral blood mononuclear cell
metabolism in quiescent, activated, and glucocorticoid-treated
states. Biosci Rep 20:289–302
65. Schrama AJ, de Beaufort AJ, Sukul YR, Jansen SM, Poorthuis BJ,
Berger HM (2001) Phospholipase A2 is present in meconium and
inhibits the activity of pulmonary surfactant: an in vitro study.
Acta Paediatr 90:412–416
66. Soukka H, Halkola L, Aho H, Rautanen M, Kero P, Kääpä P
(1997) Methylprednisolone attenuates the pulmonary hyperten-
sive response in porcine meconium aspiration. Pediatr Res
42:145–150
67. Soukka H, Jalonen J, Kero P, Kääpä P (1998) Endothelin-1,
atrial natriuretic peptide and pathophysiology of pulmonary
hypertension in porcine meconium aspiration. Acta Paediatr
87:424–428
68. Soukka H, Viinika L, Kääpä P (1998) Involvement of thromboxane
A2 and prostacyclin in the early pulmonary hypertension after
porcine meconium aspiration. Pediatr Res 44:838–842
69. Soukka HR, Ahotupa M, Ruutu M, Kääpä P (2002) Meconium
stimulates neutrophil oxidative burst. Am J Perinatol 19:279–284
70. Stahn C, Löweneberg M, Hommes DW, Buttgereit F (2007)
Molecular mechanisms of glucocorticoid action and selective
glucocorticoid receptor agonists. Mol Cell Endocrinol 275:71–78
71. Stellato C (2004) Post-transcriptional and nongenomic effects of
glucocorticoids. Proc Am Thorac Soc 1:255–263
72. Suchomski SJ, Cummings JJ (2002) A randomized trial of inhaled
versus intravenous steroids in ventilator-dependent preterm
infants. J Perinatol 22:196–203
73. Sun HW, Miao CY, Liu L, Zhou J, Su DF, Wang YX, Jiang CL
(2006) Rapid inhibitory effect of glucocorticoids on airway
smooth muscle contractions in guinea pigs. Steroids 71:154–159
74. Thomson/Micromedex (2007) Drug information for the health
care professional, vol 1. Greenwood Village, CO, p 898
75. Thung SF, Norwitz ER (2009) Endocrine diseases in pregnancy.
In: Strauss JF, Barbieri RL (eds) Yen and Jaffe’s reproductive
endocrinology: physiology, pathophysiology and clinical manage-
ment, 6th edn. Saunders Elsevier, Philadelphia, pp 615–658, 2009
76. Tølløfsrud PA, Lindenskov PH, Drevon CA, Speer CP, Seidens-
pinner S, Saugstad OD (2003) Comparison of pulmonary and
inflammatory effects of lipid- and water-soluble components in
meconium in newborn piglets. Biol Neonate 84:330–337
77. Tripathi S, Saili A (2007) The effect of steroids on the clinical
course and outcome of neonates with meconium aspiration
syndrome. J Trop Pediatr 53:8–12
78. Tripathi S, Saili A, Dutta R (2007) Inflammatory markers in
meconium induced lung injury in neonates and effect of steroids
on their levels: a randomized controlled trial. Indian J Med
Microbiol 25:103–107
79. Urbach V, Walsh DE, Mainprice B, Bousquet J, Harvey BJ (2002)
Rapid non-genomic inhibition of ATP-induced Cl
− secretion by
dexamethasone in human bronchial epithelium. J Physiol
545:869–878
80. Vázquez Nava F, Salas Ramírez E, Sánchez Núncio HR, Saldivar
GonzálezAH,BeltránSaldaňaJ,CadenaMataD,PérezRodríguezP,
Pérez Martin J, Almeida VM, Guidos Fogelbach G (2006)
Meconium aspiration syndrome, parental atopy and asthma symp-
toms in children under two years old. Rev Alerg Méx 53:130–135
81. Verriére VA, Hynes D, Faherty S, Devaney J, Bousquet J, Harvey
BJ, Urbach V (2005) Rapid effects of dexamethasone on
intracellular pH and Na
+/H
+ exchanger activity in human
bronchial epithelial cells. J Biol Chem 280:35807–35814
82. Vidyasagar D, Zagariya A (2008) Studies of meconium-induced
lung injury: inflammatory cytokine expression and apoptosis. J
Perinatol 28:S102–S107
83. Wang JY, Yeh TF, Lin YJ, Chen WY, Lin CH (1997) Early
postnatal dexamethasone therapy may lessen lung inflammation in
premature infants with respiratory distress syndrome on mechan-
ical ventilation. Pediatr Pulmonol 23:193–197
84. Wang J, Zhang L, Walther SM (2004) Administration of
aerosolized terbutaline and budesonide reduces chlorine gas-
induced acute lung injury. J Trauma 56:850–862
1504 Eur J Pediatr (2011) 170:1495–150585. Wehling M (1997) Specific nongenomic actions of steroid
hormones. Ann Rev Physiol 59:365–393
86. Wu JM, Yeh TF, Wang JY, Wang JN, Lin YJ, Hsieh WS, Lin CH
(1999) The role of pulmonary inflammation in the development of
pulmonary hypertension in newborn with meconium aspiration
syndrome (MAS). Pediatr Pulmonol 18(Suppl):205–208
87. Yamada T, Minakami H, Matsubara S, Yatsuda T, Kohmura Y,
Sato I (2000) Meconium-stained amniotic fluid exhibits chemo-
tactic activity for polymorphonuclear leukocytes in vitro. J Reprod
Immunol 46:21–30
88. Yeh TF, Srinivasan G, Harris V, Pildes RS (1977) Hydrocortisone
therapy in meconium aspiration syndrome: a controlled study. J
Pediatr 90:140–143
89. Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, Hsieh
WS, Lien YJ (1998) Early dexamethasone therapy in preterm
infants: a follow-up study. Pediatrics 101:E7
90. Yeh TF, Lin HC, Chang CH, Wu TS, Su BH, Li TC, Pyati S, Tsai
CH (2008) Early intratracheal instillation of budesonide using
surfactant as a vehicle to prevent chronic lung disease in preterm
infants: a pilot study. Pediatrics 121:e1310–e1318
91. Zhou J, Kang Z-M, Xie Q-M, Liu C, Lou S-J, Chen Y-Z, Jiang
CL (2003) Rapid nongenomic effects of glucocorticoids on
allergic asthma reaction in the guinea pig. J Endocrinol 177:R1–
R4
92. Zoban P, Cerny M (2003) Immature lung and acute lung injury.
Physiol Res 52:507–516
Eur J Pediatr (2011) 170:1495–1505 1505